by @dministrator | Jul 3, 2023 | NevakarInjectables
— Ready-to-dilute, multi-dose vials reduce compounding time and waste — Bridgewater, NJ, July 3, 2023 – Nevakar Injectables Inc. (“Nevakar”), a biopharmaceutical company developing multiple sterile injectable products for use in the critical and...
by @dministrator | Jun 6, 2023 | Vyluma
Bridgewater, NJ – June 6, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application...
by @dministrator | Jan 5, 2023 | Vyluma
Bridgewater, NJ – January 5, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it will present at the 41st annual J.P. Morgan Healthcare Conference, taking place January 9-12,...
by @dministrator | Oct 27, 2022 | Vyluma
Preliminary data from landmark, three-year, international study demonstrate safety and efficacy of NVK002 as a potential treatment for the progression of myopia in children Bridgewater, NJ – October 27, 2022 – Vyluma, Inc (“Vyluma”), a biopharmaceutical...
by @dministrator | Sep 1, 2022 | Vyluma
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia Bridgewater, NJ – September 1, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company...
Recent Comments